Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845039 · ClinicalTrials.gov registry record · Phase 2
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00845039: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT00845039 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00845039, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
Interventions
- BIOLOGICAL Cetuximab
- DRUG Irinotecan
- BIOLOGICAL IMC-A12 (cixutumumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Why NCT00845039 stopped before completion
NCT00845039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT00845039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00845039 about?
NCT00845039 is a clinical study titled "A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab". The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
What is the current status of trial NCT00845039?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2009-05. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00845039?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Irinotecan (DRUG), IMC-A12 (cixutumumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00845039?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00845039's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia